WHO certification costs, transfer pricing and commercial vehicle depreciation: capital nature, fresh TNMM review, and remand for verification.

WHO certification charges incurred to secure recognition of manufacturing facilities and vaccine quality for overseas and UN supply were treated as capital expenditure because they conferred an enduring benefit, so the disallowance was sustained. Transfer pricing adjustment for export of vaccines and royalty required reconsideration because the comparables and margin comparison were not shown to satisfy the transactional net margin method; the matter was remanded for fresh adjudication, while the necessity of royalty payment under the arrangement was upheld. Higher depreciation on motor cars as commercial vehicles also depended on the applicable depreciation schedule and Motor Vehicles Act definition, and the issue was remanded for verification.

---

---

Issues: (i) Whether WHO certification charges incurred for obtaining certification of manufacturing facilities and product quality were revenue expenditure; (ii) whether the transfer pricing adjustment in respect of export of vaccines and royalty payment was correctly determined under the transactional net margin method; (iii) whether motor cars acquired in the relevant period qualified for higher depreciation as commercial vehicles.

Issue (i): Whether WHO certification charges incurred for obtaining certification of manufacturing facilities and product quality were revenue expenditure.

Analysis: The expenditure was incurred to obtain recognition of the manufacturing facilities and the quality of the vaccine for supply to overseas markets and UN purchasing agencies. The certification secured a benefit of an enduring nature, and it was not incurred merely to improve working conditions or the manufacturing process. The alternative claim for depreciation had already been addressed by the lower authority.

Conclusion: The expenditure was held to be capital in nature and the disallowance was sustained.

Issue (ii): Whether the transfer pricing adjustment in respect of export of vaccines and royalty payment was correctly determined under the transactional net margin method.

Analysis: Under the statutory scheme, arm's length price in an international transaction is to be determined by comparing net profit margins from comparable uncontrolled transactions using the same base. The assessee's comparables were not shown to be comparable at the level of the relevant international transaction, and the adjustment made by comparing export margins with domestic margins was also not in conformity with the method. On royalty, the payment for use of technical know-how was held to be required under the arrangement, but its arm's length determination also needed fresh consideration.

Conclusion: The transfer pricing adjustments were set aside to the Assessing Officer for fresh adjudication in accordance with law, while the necessity of royalty payment was upheld.

Issue (iii): Whether motor cars acquired in the relevant period qualified for higher depreciation as commercial vehicles.

Analysis: The applicable depreciation rate depended on whether the vehicles fell within the category of commercial vehicles under the relevant depreciation schedule and the definition referenced from the Motor Vehicles Act. The record was not sufficient to conclusively establish that position.

Conclusion: The issue was remanded to the Assessing Officer for verification and fresh decision.

Final Conclusion: The cross-appeals were disposed of with partial relief, the transfer pricing and depreciation issues being remanded, and the disallowance of WHO certification expenditure being sustained.

---